Introduction: This study was conducted to compare pain response between single
uncertain. Some studies suggested that single fraction radiotherapy is equally effective to multiple fraction in providing pain relief, [4] [5] [6] [7] [8] [9] [10] [11] while others showed that higher dose fractionation provides more effective pain relief than single fractionation schedule. 12, 13 Evidence from several studies demonstrated that single fraction radiotherapy may be associated with higher rates of retreatment and pathological fracture postirradiation. 9, 10 We conducted this study to compare outcomes between single and multiple fraction palliative radiotherapy in terms of pain response, retreatment rate, and symptomatic skeletal events, and to describe potential factors affecting treatment outcomes in our patients.
| ME TH ODS

| Data collection
This is a retrospective analysis of patients with bone metastases Patients were considered eligible for this study if they had histologically proven primary malignancy with radiologically confirmed bone metastasis and received palliative radiotherapy for pain relief.
Patients were excluded if the painful site had been irradiated before the study period (ie, before 2006), the presence of spinal cord compression, pathological fracture or history of surgical intervention at treatment site, and nonsolid primary tumor. Each patient was evaluated only once, that is the first radiation treatment for one particular site.
Relevant data collected include patient demographics, primary tumor details, bone metastasis details, pain severity, analgesic consumption, radiotherapy treatment details, adverse events after radiotherapy, use of bone-targeting agents, systemic therapy, and retreatment details.
Response evaluations were documented at 4, 12, and 24 weeks after radiotherapy. Patients who died within 24 weeks of evaluation period were excluded from this study. Retreatments occurring within the evaluation period were reported as progression at evaluation endpoint and were excluded from further analysis. Retreatment outcomes were not assessed. Results were reported and compared in 2 treatment groups, that is single and multiple fractions.
| Evaluation and definition of response
| Pain score
Pain was measured by a 4-point scale with numbers 1-4 with pain documented as none-score 1, mild-score 2, moderate-score 3, and severe-score 4. 5, 14 Partial response was defined as relief of pain by at least ≥1 category (eg, severe to moderate) or score of at least 1 (eg, 4-3).
Complete response was defined as the absence of pain (pain score of 1)
at treated site. Progression was considered as an increase in pain score by ≥1 category or the need for retreatment.
| Analgesic scoring system
Patient analgesic consumption was recorded and scored as follows:
analgesic score 0-analgesic not required, score 1-nonopioid analgesic irregularly required, score 2-nonopioid analgesics regularly required, score 3-oral or parenteral opioids occasionally required, and score 4-oral or parenteral opioids regularly required. 15 The response was defined as a reduction in analgesic score by at least 1 step or an unchanged analgesic score but reduction in daily dose by ≥25%. Progression was defined as an increase in the analgesic score by ≥25% or the need for retreatment. The stable response was defined as a state between response and progression.
| International consensus endpoints
The outcomes were further analyzed using International Consensus Endpoints, which incorporates pain score response and analgesic consumption. 16 Complete response was defined as a pain score of 0 at the treated site with no increase in analgesic intake (ie, stable or reducing analgesic intake). Partial response was defined as a reduction in pain score by at least 1 (scale 1-4) at the treated site without analgesic intake or analgesic reduction by at least 25% from baseline without an increase in pain. Pain progression was defined as an increase in pain score by at least 1 above baseline at the treated site with stable analgesic usage or an increase in analgesic requirement by at least 25% from baseline with stable pain score.
| Statistical methods
The sample size was calculated using Stata software, based on the information gathered from a study by Arcangeli et al. 12 The sample size was calculated on the basis of a 0.05 alpha, with a power 80% were eligible for this study. A total of 422 patients were excluded from analysis due to prior irradiation (n = 4), nonsolid tumor (n = 5), prior surgical intervention with or without pathological fracture (n = 44), spinal cord compression (n = 113), death within 24 weeks of study period (n = 12), lost to follow-up (n = 124), and missing records (n = 120).
Baseline characteristics of the patients are summarized in Table 1 . The parallel-opposed technique was used to treat pelvis and extremity, while the direct posterior technique was used to treat spine. Treatment was delivered with a linear accelerator using megavoltage beams.
| Pain response according to fractionation group
The mean baseline pain and analgesic score at the treated site were 3.4 (SD AE 0.5) and 3.2 (SD AE 0.7), respectively. Response evaluation according to treatment groups is shown in Table 2 . There was an increasing trend of pain score response and analgesic score response noted in both the treatment groups from 4 to 24 weeks. Using chisquare test, the difference in response rates between the 2 treatment groups was not statistically significant. However, there was a statistically significant difference in analgesic score progression between the 2 fractionation groups seen at 24 weeks, P = .019.
When the results were reported in terms of International Consensus Endpoint, the difference in overall response rates and pain progression between the 2 treatment groups was not statistically significant.
| Factors affecting pain response
Several factors that could potentially affect overall pain response at 4 weeks were analyzed using simple logistic regression. The univariate analysis is shown in Table 3 , and using the preliminary main-effect model (P < .25), this suggests that gender, ECOG, primary tumor, and bone-targeting agent could possibly be significant prognostic factors affecting pain response, with significantly different rates of overall pain response, when other confounders are not adjusted.
For these variables, forward and backward logistic regression was carried out. Following this, only 2 of the variables, that is primary tumor and ECOG, were found to be significant in the main-effect model, as shown in Table 4 . There is no interaction and 
| Retreatment
The overall retreatment rate was 20.4% (n = 33). Retreatment was 
| Symptomatic skeletal events
The occurrence of pathological fracture in the treated site was seen in 4 (2.5%) patients, 2 (3%) patients in the single fraction group and 2 (2.1%) patients in the multiple fraction group. Spinal cord compression was seen in 14 (8.6%) patients, 5 (7.7%) patients in the single fraction group, and 9 (9.3%) patients in the multiple fraction group.
There was no significant difference in the occurrence of SSEs between the 2 treatment groups, P = 1.00. 
| Bone metastases
| Bone-targeting agents and systemic therapy
The administration of bone-targeting agent and systemic therapy in both the fractionation groups is shown in Table 5 . Mean time from diagnosis of bone metastases to initiation of bone-targeting agent was 44.9 (SD AE 58) weeks. There was a significant association for usage of bone-targeting agents and occurrence of pathological fracture and cord compression (P = .004).
| DISCUSSION
The results of our study showed that there is no significant difference in pain relief between single and multiple fraction radiotherapy for palliation of painful bone metastases. This is consistent with several published studies [5] [6] [7] and meta-analyses. 10 the palliation of painful bone metastases showed a higher overall response rate for higher doses, that is an overall response rate of 84% for 10 Gy and 72% for 8 Gy in evaluable patients, which was representative of the single fraction doses that were used in our study, as 92.3% of our patients were prescribed 8 Gy and the remaining 10 Gy.
When results were reported using International Consensus Endpoints, we obtained an overall response rate of 56.2% and 62.3% at 4 and 12 weeks, respectively, in the entire cohort of patients. Our results were comparable with published data of overall response rates in evaluable patients according to International Consensus Endpoint at 1 month of 58% and 3 months of 67%. 20 The reported estimated spinal adverse event (SAE) rate (which include uncontrolled pain) of >40% at 6 months 21 could explain the significant requirement for more analgesia at 24 weeks that was seen in our study.
There was a significantly higher overall response rate observed in patients with ECOG < 2 and primary tumors of breast and prostate when compared to other primary tumors, which was compatible with evidence which demonstrated that patients with breast and prostate cancer had the best response rate. 9 In addition to this, a study has reported that the single fraction group was associated with fourfold greater retreatment rate and higher pathological fracture rate. 9 Our study did not demonstrate this. We found higher retreatment rates in the single fraction group, but this was not statistically significant. We obtained a retreatment rate of 24.6% in the single fraction group and 17.5% in the multiple fraction group, which was higher as compared to published data of 21%, 19 18.2% 21 in single fraction group and 6% 21 in the multiple fraction group. The highest percentage of retreatment was seen in patients with lung primary, which could be due to the effect of tumor histology. 9, 12 At 4 weeks of evaluation endpoint, there were 3 (9%) retreatments involving the spine, 2 of them were in the single fraction group. The use of single fraction radiotherapy in patients with high spinal instability neoplastic score (SINS ≥ 11) was associated with higher incidence of SAEs, with a reported cumulative incidence first with SAE rate at 30 days of 6.8% in the single fraction group and 3.5% in the multiple fraction group. 21 Our results showed a lower pathological fracture rate of 3% in the single fraction group compared to 4% 9,19 and 13.6% 21 that have been reported. However, the pathological fracture rate obtained in the multiple fraction group of 2.1% was similar to published data of 2% 9 and 3%. 21 As for cord compression rate, we obtained rates of The significant association between the development of pathological fracture and cord compression with the usage of bone-targeting agents is consistent with published trials on the efficacy of bonetargeting agents in reducing the risk of skeletal-related events. 22, 23 There were several limitations to our study. Given the retrospective nature of this study, we were limited by the availability of data.
Firstly, as our primary objective was to assess pain response, patients who did not have data or follow-up notes following irradiation were excluded. This included patients who had died within evaluation period of 24 weeks. We acknowledge that the number of deaths reported in this study may not be accurate as there could be more deaths in the lost to follow-up and missing notes group that we were not able to trace. Hence, our study population may not be representative of the actual situation.
Secondly, we realized that patient-reported outcomes were as important as physician-assessed outcomes, as it provides evaluation of response on the patient's perspective. Results based on patient-reported outcomes showed an improvement of 70% in pain with no difference between single and multiple fraction groups. 24 The choice of single fraction radiotherapy is affected by cultural differences, physicians' experience, location of training, and practice location. 25 The reported single fraction utilization rate in Canada was 49.2%, 25 as compared to the United States of 4.7%. 26 There are no trials reporting on the single fraction utilization rate in Asian countries to date. As for cultural differences, 76% of Canadian patients favored single fraction 27 while 85% of Asian patients preferred the multiple fraction schedule. 28 Patients' preference toward treatment needs to be considered as well as 84% of Asian patients expressed positive opinions about being involved in the decision-making process. 28 Therefore, our study could be improved by including outcome assessment by physician and patient, SINS for patients with spinal metastases, patient involvement in treatment decision making, and exploration on physician judgment in choosing radiotherapy prescription. A prospective randomized trial should be performed in the future to verify our results. Importantly, despite our limitations, we were able to obtain comparable pain response rates to those found in the literature.
In conclusion, our study showed that there is no significant difference in terms of pain response, retreatment rate, and SSEs between single fraction and multiple fraction radiotherapy in patients treated for uncomplicated bone metastases. Single fraction radiotherapy should be the standard treatment and prescribed more frequently as it is more convenient and cost-effective.
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